New developments in oral contraception: clinical utility of estradiol valerate/dienogest (Natazia®) for contraception and for treatment of heavy menstrual bleeding: patient considerations

Anita L. Nelson
In: Open Access Journal of Contraception · 2012 · pp. 49 · doi:10.2147/oajc.s26225 · W2061870332
article OA: gold CC0 ⤵ 1 in-corpus citation
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This review examines the contraceptive efficacy, bleeding patterns, safety, and tolerability of estradiol valerate/dienogest (Natazia), a new oral contraceptive approved for both contraception and treatment of heavy menstrual bleeding.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This narrative review examines the oral contraceptive estradiol valerate/dienogest (Natazia®, also known as Qlaira®), focusing on its multiphasic formulation with a shortened hormone-free interval and summarizing pivotal clinical trial results on contraceptive effectiveness, bleeding patterns, and safety/tolerability. It also reviews trial evidence for use in treating heavy menstrual bleeding in women who desire oral contraception, and discusses findings from comparisons with other formulations for “menstrually-related” symptoms and related effects such as potential female sexual dysfunction. The paper’s main limitation is that, as a review centered on clinical utility and counseling considerations, it does not present new primary experimental data. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Abstract: Natazia ® is a new oral contraceptive with estradiol valerate and dienogest in a unique multiphasic formulation that includes a shortened hormone-free interval. This new formulation has been approved for both contraception and also as a treatment for heavy menstrual bleeding in women who desire to use oral contraceptives as their method of birth control. It is marketed in the US as Natazia ® and elsewhere as Qlaira ® . This article will review the properties of each of the major new features of this pill: estradiol used in place of ethinyl estradiol, dienogest as the progestin, and the unique dosing pattern of this product. It will also summarize the results of the pivotal clinical trials of contraceptive effectiveness, bleeding patterns, safety and tolerability. The lessons learned from the clinical trials about the effectiveness of this formulation in the treatment of excessive menstrual bleeding will be summarized. Also, results of trials comparing this new pill to other popular formulations for "menstrually-related" symptoms and for potential female sexual dysfunction related to use of oral contraceptives will be presented. This review will suggest how all this information might be used to counsel women about how to use this pill most successfully. Keywords: oral contraceptives, estradiol valerate, dienogest, heavy menstrual bleeding, menorrhagia, dynamic dosing

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (88)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK